TRCT
AURA icon

Tower Research Capital (TRC)’s Aura Biosciences AURA Stock Holding History

Tower Research Capital (TRC)’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.2K Buy
3,913
+1,958
+100% +$11.2K ﹤0.01% 3288
2025
Q4 		$10.7K Sell
1,955
-261
-12% -$1.55K ﹤0.01% 3726
2025
Q3 		$13.7K Sell
2,216
-4,156
-65% -$27.2K ﹤0.01% 3662
2025
Q2 		$39.9K Buy
6,372
+2,104
+49% +$12.3K ﹤0.01% 3165
2025
Q1 		$25K Buy
4,268
+1,166
+38% +$8.82K ﹤0.01% 2767
2024
Q4 		$25.5K Buy
3,102
+403
+15% +$3.79K ﹤0.01% 3006
2024
Q3 		$24K Sell
2,699
-1,983
-42% -$17K ﹤0.01% 3137
2024
Q2 		$35.4K Buy
4,682
+1,528
+48% +$11.2K ﹤0.01% 3361
2024
Q1 		$24.8K Sell
3,154
-1,143
-27% -$9.48K ﹤0.01% 2806
2023
Q4 		$38.1K Sell
4,297
-2,307
-35% -$19.5K ﹤0.01% 3302
2023
Q3 		$59.2K Buy
6,604
+4,758
+258% +$51.2K ﹤0.01% 2404
2023
Q2 		$22.8K Buy
1,846
+770
+72% +$8.23K ﹤0.01% 3270
2023
Q1 		$10K Sell
1,076
-2,459
-70% -$25.5K ﹤0.01% 4326
2022
Q4 		$37K Buy
3,535
+2,273
+180% +$28.9K ﹤0.01% 2553
2022
Q3 		$23K Sell
1,262
-2,687
-68% -$40.7K ﹤0.01% 3804
2022
Q2 		$56K Buy
3,949
+2,840
+256% +$47K ﹤0.01% 2774
2022
Q1 		$24K Buy
1,109
+451
+69% +$8.59K ﹤0.01% 3353
2021
Q4 		$11K Buy
+658
New +$11.8K ﹤0.01% 4383

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Tower Research Capital (TRC)'s AURA Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Aura Biosciences (AURA) stake by 100% in Q1 2026, buying an estimated $11.2K and bringing the position to 3,913 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3288.

Tower Research Capital (TRC) first reported a position in AURA in Q4 2021 and has held it in 18 quarters since. The position peaked at $59.2K in Q3 2023. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • Tower Research Capital (TRC) held 3,913 shares of Aura Biosciences worth $26.2K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,958 Aura Biosciences shares in Q1 2026, an estimated $11.2K.
  • Aura Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3288 holding.
  • Tower Research Capital (TRC) first reported a position in Aura Biosciences in Q4 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Aura Biosciences position peaked at $59.2K in Q3 2023.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.